Journal and News Scan

This study analyzed long-term risk factors for compensatory sweating following bilateral endoscopic thoracic sympathectomy (BETS) in 98 patients between 2010 and 2023. Compensatory sweating as a side effect was classified as mild, moderate, or severe using the STS guidelines, while quality of life (QOL) was assessed via the Hyperhidrosis Disease Severity Scale. Logistic and Bayesian regression models were used to identify predictors of compensatory sweating. 
 
Overall, the procedure achieved a success rate of 94.38 percent, with 34.69 percent of patients reporting compensatory sweating, mostly mild (26.53 percent). Nearly all patients achieved significant reduction in sweating (≥50 percent in 97.95 percent; ≥80 percent in 94.89 percent). 
 
Protective factors highlighted were high hemoglobin levels and marijuana use. Conversely, tobacco smoking and the presence of combined hand-axillary hyperhidrosis increased the risk of compensatory sweating. Identifying at-risk patients, such as those who smoke tobacco and those with low hemoglobin levels, can help improve outcomes by managing expectations when undergoing (BETS). 

This article summarizes the use of artificial intelligence (AI) using ChatGPT to correlate decision-making in a pediatric surgery cardiovascular surgery conference by comparing expert consensus with results from ChatGPT. A total of 37 cases of varying complexity were submitted to ChatGPT, and the software was asked to summarize the case, provide a diagnosis, and suggest a treatment plan, including possible surgical options. Interestingly, there was a consensus on treatment plan approximately 94 percent of the time for simple cases; however, this dropped to only 25 percent for complex cases. This study further highlights the role of AI in medical decision-making, emphasizing its potential as a tool that can aid the medical community and the public in some ways while also cautioning against its pitfalls, which could lead to misinformation and inaccuracies. 

This article presents a comprehensive epidemiological analysis of lung cancer, focusing on subtype-specific patterns worldwide. Using data from GLOBOCAN 2022 and other international cancer registries, the study estimated more than 2.48 million new lung cancer cases globally in 2022, with adenocarcinoma being the most common subtype in both men and women. Geographic variation was significant, with East Asia showing the highest incidence of adenocarcinoma and Eastern Europe leading in squamous and small-cell carcinoma among men. Importantly, the study attributed more than 190,000 adenocarcinoma cases to ambient particulate matter (PM) pollution, underscoring the role of environmental exposure in disease burden. Temporal and generational analyses across 19 countries revealed diverse trends in subtype incidence, reflecting evolving risk factors. 
 
This article is important to the global cardiothoracic surgery community as it informs clinical practice, resource planning, and prevention strategies by highlighting shifting patterns in lung cancer subtypes, with implications for early detection and tailored surgical approaches. 

Long-term evidence about bioprosthetic tricuspid valve replacement is scarce. This study aims to investigate the long-term clinical outcomes of patients who underwent tricuspid valve replacement with bioprostheses. This multicenter retrospective study included patients from 10 high-volume centers in seven different countries who underwent tricuspid valve replacement with bioprostheses. Echocardiographic and clinical data were reviewed, and long-term outcomes were investigated. Of the 675 patients, isolated tricuspid valve replacement was performed in 358 patients (53 percent), while 317 (47 percent) underwent concomitant procedures. Between these two groups, patients who underwent combined procedures reported a significantly higher incidence of infection, atrioventricular block, multiorgan failure, longer ICU and hospital stays, and higher 30-day mortality compared to patients who underwent isolated procedures. The overall 30-day mortality occurred in 70 patients (10.4 percent) (46 [14.6 percent] in the combined group vs 24 [6.74 percent] in the isolated group, p = 0.001). During follow-up, there was a continuous rate of attrition due to death, with cumulative incidences of death at five, 10-, and 15-years being 27.2 percent, 46.2 percent, and 60.6 percent, respectively. In contrast, the risk of reintervention started to significantly increase after 10 years of follow-up, with cumulative incidences of reintervention being 6.1 percent, 10.8 percent, and 23.3 percent, respectively. Freedom from tricuspid valve reintervention, pacemaker implantation, tricuspid valve endocarditis, and major thromboembolic events at 15 years were 56.5 percent,77.3 percent, 84.0 percent, and 86.4 percent, respectively. The authors conclude that tricuspid valve replacement with bioprostheses is an effective treatment, despite being associated with relatively high early and long-term mortality. However, the risk of structural valve degeneration rises significantly after 10 years.